Perlegen
Somebody sent me a private message about this and I thought that I would reply publicly. Perlegen look superficially to have compelling technology that is in DNAP's domain. Here is what DNAP said about competition in the last 10K:
"Our expertise finding and modeling AIMs form the cornerstone of our strategy to penetrate the consumer products, forensic and pharmacogenomics markets with our genomic testing products. We are one of the first companies to develop infrastructure for this purpose. Due to limited competition in the field of complex genomics classification to date, these market opportunities remain attractive. Other companies and researchers seeking to develop genomic classification or diagnostic products to bring to market are currently screening hundreds of thousands to millions of markers across the genome. This process is not commercially viable for many markets, due to cost."
"By developing unique genome maps, however, we allow researchers to efficiently and cost effectively discover and decipher complex, common genetic traits. Our AIMs are novel because they allow a genome screen to be accomplished with as few as 2,000 markers, making it cost effective to develop genomic based tests."
"We compete against a limited number of companies in pharmacogenomics, including Gennaissance, Seryx, Variagenics, and Genset; deCODE Genetics, Celera Genomics, Incyte Genomics, Orchid BioSciences, and Sequenom. The latter two principally offer tools and services for sequencing and scoring SNPs, while Celera and Incyte are involved primarily in creating SNP databases. DeCODE Genetics focuses on gene discovery, drug target validation, as well as pharmacogenomic analysis through use of its proprietary informatics system and its Icelandic Health Sector Database. Genset also has an interest in pharmacogenomics through its development of genomic markers using its proprietary technology platform; however, it has dedicated its resources to internal drug discovery and development in the areas of central nervous system and metabolic disorders."
Note that Perlegen are not listed as a competitor.
